The top result came from a confined 400 mg cohort over four weeks, though Biomea says placebo weight loss muddies it. The company now wants a partner to fund phase II.
Recap by typeshit. Full story at Yahoo Finance.
The study of over 87,000 matched patients 65 and up also found 28% fewer liver decompensation events, but no drop in heart attack or stroke and more osteoporosis diagnoses.
18:05
Dr. Stirrett walks through three pointers for people on tirzepatide, framed as part of a broader GLP-1 guide. His advice, not a set protocol.
He walks through an Azoury et al study in the October 2026 Plastic and Reconstructive Surgery that uses global health network data to compare the two weight loss routes.
The claim credits GLP-1 drugs' effects on insulin sensitivity and inflammation for changes in dermatologic conditions. No study is cited.
A basic primer that walks through how amino acid makeup shapes what a peptide does. Evergreen material with little that's new.
The Ministry of Health is asking the healthcare sector to promote careful use of weight and metabolic drugs, warning that misuse could carry risks.
Loading…